argenx

Industriepark 7
9052 Zwijnaarde
BE
argenx
Foundation date
04/09/2009
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Celyad Oncology appoints Georges Rawadi as its new CEO
Tuesday March 28th 2023
Read more
-
BioLizard appoints Paul Vauterin as Chief Technology Officer
Monday March 27th 2023
Read more
-
ImmuneWatch receives Antwerp Innovation grant to accelerate vaccine development with AI
Monday March 27th 2023
Read more